CSBio CSBio

X
[{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone Skin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"}]

Find Novel Dermatology Drugs in Preclinical Development in GERMANY

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future License Agreement.

            Lead Product(s): Staphylococcus epidermidis strain

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY